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ABSTRACT: 
Phospholipase A2 (PLA2) was known to regulate inflammation and hence it was considered as a 
validated drug-target by medicinal chemists. In this report, we have identified and considered 
highly ranked ligand of ZINC-drug-like compounds database, which targets PLA2 via 
MOLPRINT-2D based chemoinformatic drug-design approach. The computationally predicted 
lead molecule was found to contain the core moiety of chromene ring, which was well known for 
its varied biological properties. Here, a novel and efficient retro-synthetic protocol for the 
synthesis of highly substituted chromene libraries was made. One-pot synthesis of chromene was 
carried out by using different aromatic primary alcohols, malanonitrile and 4-hydroxy coumarin 
in the presence of mild oxidant mixture called T3P
®
-DMSO, followed by Suzuki coupling 
reaction to obtain the lead molecules. All the tested compounds of chromene series displayed the 
inhibition of the venom PLA2 with a range from 12 to 68 µM. Among the tested compounds, 2-
amino-4-(2'-methyl-[1,1'-biphenyl]-4-yl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-
carbonitrile (7b) showed maximum inhibitory efficacy against venom PLA2 with an IC50 value 
of 12.5 µM. Furthermore, the designed PLA2 ligands bound to the active site of venom PLA2, 
whose binding affinity was comparable to nimesulide, indicate the chromene moiety containing 
ligands could be novel lead-structure that serves as anti-inflammatory agents. 
Keywords: Retro-synthesis, 2-amino chromene-3-carbonitrile, MOLPRINT 2D, Snake venom 
PLA2. 
Page 2 of 33RSC Advances
R
S
C
A
dv
an
ce
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
13
 O
ct
ob
er
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
N
EB
RA
SK
A
 o
n 
15
/1
0/
20
15
 0
7:
06
:3
3.
 
View Article Online
DOI: 10.1039/C5RA13085A
INTRODUCTION 
Phospholipase A2 (PLA2) was the most-studied membrane-bound enzyme with a 
molecular weight of 14 kDa
[1-3]
.  It was a Ca
2+
-dependent and disulphide-rich enzyme, and 
mostly present in mammalian tissues and in the venoms of insects and snakes
[4]
. It hydrolyzes the 
phospholipids from cellular membranes and lipoproteins at the sn-2 position releasing 
lysophospholipids and free fatty acids
[5]
. PLA2s are known to aid the production of eicosanoids, 
prostaglandins, leukotrienes and platelet-activating factors (PAF), which exert hormone-like 
function orchestrating various physiological events at lower concentrations 
[2]
. However, higher 
levels may induce serious pathological conditions such as inflammation, arthritis, atherosclerosis 
and sepsis. Hence, PLA2 along with cyclooxygenases and lipoxygenases regulate inflammation 
and associated inflammatory diseases. Among the secretary PLA2s, group IIA was known to 
play a key role in both acute and chronic inflammation, which was regulated by multiple 
intracellular signalling cascades
[6]
. Besides regulation of human diseases, snake venom 
pathology was largely attributed to the presence of PLA2. Snake venoms have been 
demonstrated to be a complex mixture of PLA2, matrix metalloproteinase, hyaluronidases and 
other toxic non-enzymatic peptides
[7]
. The combined action of these enzymatic and non-
enzymatic venom components are known to induce proteolysis, haemorrhage, necrosis, altered 
haemostasis, shock and several other neurological dysfunctions 
[8]
. Among them, venom-induced 
necrosis, edema and anticoagulation are directly accredited to the myotoxic PLA2 and other 
myotoxins present in the venom.  
In view of this, inhibition of PLA2 has been considered as a prime target in the 
management of inflammatory diseases and snakebites. Thus, the aim of research in this 
field was to identify safe and effective PLA2 inhibitors. The higher structural similarity 
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between the snake venom sPLA2 and of humans suggests using snake venom PLA2 
inhibitors to design novel drugs aiming human inflammatory diseases and vice versa 
[9, 10]
. 
Also, the active site of sPLA2 was composed of substrate binding hydrophobic region and 
substrate cleaving hydrophilic region, hence it was further requirement that a PLA2 
inhibitor must bear hydrophobic and hydrophilic moieties in it
[11]
. To date, several 
synthetic
[12] 
and natural
[13]
 inhibitors have been reported as PLA2 inhibitors. However this 
search had limited success in finding novel class molecules which bear both hydrophobic 
and hydrophilic moieties. 
In continuation of our ongoing report on synthetic inhibitors that targets PLA2
[14-15]
, and 
other drug-targets
[16-22]
, presently, we herein, report the design of novel drug-like small 
molecules via chem-informatics approaches followed by synthesis of lead structure, via a retro-
synthetic approach as the starting point. Furthermore, we validate the efficacy of these inhibitors 
against snake venom VRV-PL-VIIIaPLA2 isolated from vipera russelli venom and driven by the 
in silico molecular interaction studies, this enabled us to discover novel inhibitors that target 
PLA2. 
RESULTS AND DISCUSSION 
MOLPRINT 2D-based identification of drug-like compounds targeting PLA2: 
A MOLPRINT-2D PLA2 model was queried with the drug-like molecules of ZINC database 
[23]
. 
The top ranked compounds are summarized in Table 1 & Figure 1. Among the ranked 
compounds, ZINC00625534 (DCMB) was ranked 4
th
. This DCMB was considered as lead 
molecule as other top ranked compounds failed to contain both hydrophobic and hydrophilic 
moiety. Since DCMB contain ester linkage, we designed and prepared DCMB analogues.  
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Synthesis of DCMB analogues: 
The lead PLA2 inhibitor ZINC00625534 (DCMB) contains hydrophilic amino, lactone, nitrile, 
methoxy and ester groups also hydrophobic aromatic rings. To achieve an effectual interaction 
between sPLA2 active site and an inhibitor, we have replaced the ester group of DCMB by C-C 
bond which enhances hydrophobicity of the inhibitor. To start with synthesis of DCMB 
analogues (2-amino chromene-3-carbonitriles), we have employed retro-synthetic approach 
(Supplementary Figure S1) where primary alcohol (1) and malanonitrile (2) reacts in presence of 
T3P
®
-DMSO and ethyl acetate as solvent to give swern oxidized product which further on 
Knoevenagel condenzation gives product (3)
[24]
. The intermediate 3 undergoes Michael 
cyclization with 4-hydroxy coumarin (4) to form compound 5. Further, Suzuki coupling reaction 
of 5 with aromatic and pyridine boronic acids (6) where we have used [1,10-
bis(diphenylphosphino)ferrocene]dichloro palladium catalyst (Pd(dppf)Cl2) and SCS-Bi2O3base 
in tetrahydrofuran solvent given DCMB analogue 7
[25]
. The detailed chemical synthesis and 
characterization of DCMB analogs was presented (Figure 2).  
 
Neutralization of snake venom PLA2 by the lead molecule libraries: 
In order to test the efficacy of the synthesized inhibitors, they were tested against snake 
venom PLA2 called VRV-PL-VIIIa isolated from vipera russelli venom. Inhibitory 
effects of the series of lead molecules against PLA2 were tabulated (Table 2). All the 
tested compounds displayed the inhibition of the venom PLA2 with a range from 12 to 68 
µM. Among the tested compounds, 7b showed maximum inhibitory efficacy against 
PLA2 with an IC50 value of 12.5 µM (Table 3). Till date, several inhibitors from 
synthesis, and also from various organisms including marine sponges, snakes, bees, plants 
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and mammals have been reported. However, this happens to be the first report that the 
novel chromene molecule, which displayed a potent inhibition of snake venom PLA2. 
 
In silico interaction studies of novel ligands that targets PLA2: 
In order to understand structure-based correlation with compound affinity, we conducted 
molecular docking studies using crystal structure of PLA2 from Russel's viper that bound to 
nimesulide (PDB: 1ZWP)
[26]
. The chromene ligands were docked into the PLA2 structure using 
MOE
[27]
. We found the cyano functionality of our ligand series consistently replacing the nitro 
group of nimesulide and forming hydrogen bonds to the backbone nitrogen of Gly-32. The 
exposed binding site of PLA2 allows for two binding modes of our compounds including these 
interactions (see Figure 3). Both of them form π-π interactions with the readily accessible indole 
moiety of Trp-31. Different orientation of the core ring system either allows the amine function 
of the ligands to form hydrogen bonds to the carboxylate of Asp-49 or to the backbone carbonyl 
of Gly-30. Both predicted binding modes are shown in Figure 3 for the two compounds 7a and 
7b with highest PLA2 inhibition in vitro. Structure-activity relationships within the ligand series 
are not straightforward to interpret as group-wise contributions since binding modes of the 
ligands might change and thus give rise to different molecular interactions between PLA2 and 
the respective compounds. 
MATERIALS AND METHODS 
In silico design of novel small molecule that target PLA2. 
The ligand similarity searching protocol, as implemented in MOLPRINT-2D, was trained using 
bioactivity data from the ChEMBL database for the target PLA2. Bioactivity training data was 
extracted from the ChEMBL16 database where activity values (IC50 / EC50 / Ki / Kd) less than 
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or equal to 10µM, and a ChEMBL confidence score of 8 or greater for ‘binding’ or ‘functional’ 
assays, giving 2,499 active compounds. 1,426 compounds exceeded the 10µM threshold, which 
were considered to be inactive and used as negative bioactivity training data. MOLPRINT 2D 
descriptors were generated for the complete data set of active and inactive compounds 
[28, 29]
. The 
Naïve Bayes learner was subsequently trained on the training compounds and queried with the 
MOLPRINT 2D fingerprints of 7,228 drug-like compounds of ZINC database. The ZINC 
molecules were ranked in terms of ‘probability of activity’ scores generated by models. A 10-
fold cross validation with a 50/50 random split of both active and inactive structures was 
performed, confirming the predictive power of the models.  
Chemical Synthesis: 
All reagents were commercially available reagent grade were used without further purification. 
Thin layer chromatography (TLC) was conducted on 0.25 mm silica gel plates (60F254, Merck). 
Column chromatography separations were obtained on silica gel (200-400 mesh). IR spectra 
were recorded on Bruker FTIR spectrophotometer. 
1
H NMR spectra were recorded on 
BrukerAvance-300 instrument in CDCl3 solvent. 
13
C NMR spectra were obtained on 
BrukerAvance-300 instrument at 75 MHz in DMSO-d6 solvent (few on Agilent NMR instrument 
in CDCl3 solvent). Chemical shifts are expressed in ppm downfield relative to TMS. Mass 
spectra were recorded on Agilent LC-MS and the elemental analyses were carried out using an 
Elemental Vario Cube CHNS rapid Analyzer. 
 
General procedure for synthesis of DCMB analogues: To the solvent mixture of ethyl acetate 
and DMSO (1.5 ml: 0.75ml = 2: 1 ratio) 4-bromo/3-bromo-4-methoxy benzyl alcohol 1 (1.0 
mmol) and malanonitrile 2 (1.2 mmol) are added in presence of T3P
®
 (2.5 mmol, 50% solution in 
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ethyl acetate) at room temperature, which undergo in-situ Swern oxidation followed by 
Knoevenagel condensation to yield corresponding alkene 3 within 10 minutes. Complete 
formation of alkene 3 was confirmed by TLC using hexane:EtOAc (7:3) system and has been 
observed at Rf 0.78 under ultraviolet (UV) light. Without isolating the alkene 3, to this reaction 
mixture 4-hydroxy coumarin 4 (1.0 mmol) was added and stirred for 2-3 hours at room 
temperature to form compound 5
[30]
. Reaction was monitored by TLC (Hexane: EtOAc 7:3) and 
the compound 5 has been observed at Rf 0.42 under UV light. After completion of the reaction, 
the mixture was diluted with about 5 ml of distilled water. The product was extracted with 10 ml 
of ethyl acetate and the combined organic layers were washed with 10 ml of distilled water, 
followed by 5 ml of brine solution. The organic phase was dried over anhydrous Na2SO4. The 
solvent was removed under reduced pressure to afford a pure product. Compound 5 was obtained 
with 98% yield.  
Further the compound 5 (1 mmol) heated to 70 
o
C with variety of aryl/hetero boronic acids 6 (1.2 
mmol) in presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml 
water and 4 ml of tetrahydrofuran solvent for 8-10 hours to obtain crude DCMB analogues (7 a-
n) (Table 2). The formation of final products 7(a-n) was monitored by TLC (Hexane: EtOAc 
8:2). This was further purified by column chromatography using hexane: ethyl acetate as eluent. 
The final product 7(a-n) was eluted with 15% hexane:ethyl acetate system (85ml hexane: 15ml 
ethyl acetate). Thus obtained DCMB analogues were enantiomers and are isolated as recemic 
mixtures. These DCMB analogues are confirmed by spectral analysis without separation of the 
recemic mixtures.. Spectral properties were consistent with their assigned structures.  
7a 4-([1,1'-biphenyl]-4-yl)-2-amino-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-
carbonitrile: This compound was obtained by heating 2-amino-4-(4-bromophenyl)-5-oxo-4,5-
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dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 5) and phenyl boronic acid 
6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) 
base in 1 ml water and 4 ml of tetrahydrofuran solvent for 8 hours. 7a has been observed on TLC 
at Rf 0.58 under UV light and was isolated as white solid by column chromatography with 15% 
hexane:ethyl acetate system (85ml hexane: 15ml ethyl acetate).  
IR νmax: 3323cm
-1 
ν(NH2), 2194cm
-1 
ν(CN), 1673cm
-1
ν(c-o),1049cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 7.912-7.206 (m, 13H, Ar-H), 4.856 (s, 1H, methine); 
13
C NMR (CDCl3, 75MHz) δ 
161.13, 160.57, 158.53, 156.08, 148.44, 145.95, 134.46, 130.35, 129.75, 128.17, 126.57, 125.46, 
124.53, 123.48, 117.66, 112.60, 103.83, 60.20, 35.13; LCMS (MM:ES+APCI) (M+H)
+
 393; 
Anal.Calcd for C25H16N2O3 : C 76.62, H 4.11, N 7.14;  Found: C 76.14, H 4.19, N 7.42. 
7b 2-amino-4-(2'-methyl-[1,1'-biphenyl]-4-yl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-
carbonitrile: This compound was obtained by heating 2-amino-4-(4-bromophenyl)-5-oxo-4,5-
dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 5) and o-tolylboronic acid 
6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) 
base in 1 ml water and 4 ml of tetrahydrofuran solvent for 7 hours. 7b has been observed on TLC 
at Rf 0.59 under UV light and was isolated as yellow solid by column chromatography with 15% 
hexane:ethyl acetate system (85ml hexane: 15ml ethyl acetate).  
IR νmax: 3256cm
-1 
ν(NH2), 2196cm
-1 
ν(CN), 1680cm
-1
ν(c-o),1047cm
-1 
ν(C=O);
1
H NMR (CDCl3, 300 
MHz):- δ 7.831-7.295 (m, 12H, Ar-H), 4.161 (s, 1H, Methine), 3.295 (s, 2H, -NH2), 2.254 (s, 
3H, -CH3); LCMS (MM:ES+APCI) (M+H)
+
407; Anal.Calcd for C26H18N2O3: C 76.83, H 4.46, 
N 6.89;  Found: C 76.91, H 4.53, N 6.81. 
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7c 2-amino-4-(3'-methoxy-[1,1'-biphenyl]-4-yl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-
carbonitrile: This compound was obtained by heating 2-amino-4-(4-bromophenyl)-5-oxo-4,5-
dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 5) and (3-
methoxyphenyl)boronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 
mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 4 ml of tetrahydrofuran solvent for 8 
hours. 7c has been observed on TLC at Rf 0.52 under UV light and was isolated as white solid by 
column chromatography with 16% hexane:ethyl acetate system (84ml hexane: 16ml ethyl 
acetate). 
IR νmax: 3293cm
-1 
ν(NH2), 2193cm
-1 
ν(CN), 1673cm
-1 
ν(c-o),1048cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 8.000-7.978 (m, 3H, Ar-H), 7.792-7.746 (m, 2H, Ar-H), 7.552-7.521 (m, 2H, Ar-H), 
7.434-7.394 (m, 4H, Ar-H), 7.257 (s, 1H, Ar-H), 3.884 (s, 1H, Methine), 3.846 (s, 3H, -OCH3); 
13
C NMR (DMSO-D6, 75MHz) δ 162.52, 160.19, 143.72, 134.25, 131.56, 126.11, 125.87, 
125.09, 124.35, 123.46, 122.92, 121.62, 120.95, 120.12, 117.57, 114.29, 112.52, 99.35, 57.28, 
52.25, 35.28; LCMS (MM:ES+APCI) (M+H)
+
 423; Anal.Calcd for C26H18N2O4 : C 73.92, H 
4.29, N 6.63;  Found: C 73.88, H 4.32, N 6.59. 
7d 2-amino-5-oxo-4-(2'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-4,5-dihydropyrano[3,2-
c]chromene-3-carbonitrile: This compound was obtained by heating 2-amino-4-(4-
bromophenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 5) 
and (2-(trifluoromethyl)phenyl)boronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 
catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 4 ml of tetrahydrofuran 
solvent for 9 hours. 7d has been observed on TLC at Rf 0.50 under UV light and was isolated as 
grey solid by column chromatography with 16% hexane:ethyl acetate system (84ml hexane: 
16ml ethyl acetate). 
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 IR νmax: 3292cm
-1 
ν(NH2), 2199cm
-1 
ν(CN), 1669cm
-1 
ν(c-o),1033cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 7.831-7.260 (m, 12H, Ar-H), 4.714 (s, 1H, Methine); 
13
C NMR (CDCl3, 75MHz) δ 
162.57, 161.43, 159.27, 158.12, 143.29, 141.25, 135.04, 132.81, 128.77, 126.92, 126.03, 125.12, 
124.69, 123.14, 121.20, 120.07, 118.77, 116.83, 110.32, 100.05, 58.23, 38.48; LCMS 
(MM:ES+APCI) (M+H)
+
 461; Anal.Calcd for C26H15F3N2O3 : C 67.83, H 3.28, N 12.38;  Found: 
C 67.90, H 3.31, N 12.41. 
7e 2-amino-4-(4'-chloro-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-5-oxo-4,5-
dihydropyrano[3,2-c]chromene-3-carbonitrile: This compound was obtained by heating 2-
amino-4-(4-bromophenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) 
(compound 5) and (4-chloro-3-(trifluoromethyl)phenyl)boronic acid 6(1.2 mmol) at 70 
o
C in 
presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 
4 ml of tetrahydrofuran solvent for 8.5 hours. 7e has been observed on TLC at Rf 0.50 under UV 
light and was isolated as white solid by column chromatography with 16% hexane:ethyl acetate 
system (84ml hexane: 16ml ethyl acetate). 
IR νmax: 3293cm
-1 
ν(NH2), 2200cm
-1 
ν(CN), 1667cm
-1 
ν(c-o),1050cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 7.842-7.260 (m, 11H, Ar-H), 4.851 (s, 1H, Methine); 
13
C NMR (CDCl3, 75MHz) δ 
161.08, 160.50, 158.19, 141.89, 135.08, 132.50, 130.19, 128.11, 127.47, 126.09, 124.05, 123.74, 
122.29, 121.08, 119.85, 117.64, 115.24, 111.48, 101.56, 60.15, 36.22; LCMS (MM:ES+APCI) 
(M-H)
-
 493; Anal.Calcd for C26H14ClF3N2O3 : C 63.11, H 2.85, N 5.66;  Found: C 63.15, H 2.89, 
N 5.70. 
7f 2-amino-5-oxo-4-(4-(pyridin-3-yl)phenyl)-4,5-dihydropyrano[3,2-c]chromene-3-
carbonitrile: This compound was obtained by heating 2-amino-4-(4-bromophenyl)-5-oxo-4,5-
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dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 5) and pyridin-3-ylboronic 
acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 
mmol) base in 1 ml water and 4 ml of tetrahydrofuran solvent for 8.5 hours. 7f has been observed 
on TLC at Rf 0.55 under UV light and was isolated as white solid by column chromatography 
with 15% hexane:ethyl acetate system (85ml hexane: 15ml ethyl acetate). 
IR νmax: 3323cm
-1 
ν(NH2), 2195cm
-1 
ν(CN), 1668cm
-1
ν(c-o),1042cm
-1 
ν(C=O);
1
H NMR (CDCl3, 300 
MHz):- δ 8.922-8.918 (s, 1H, Ar-N-CH), 8.688-8.673 (d, 1H, Ar-H), 8.568-8.548 (d, 1H, Ar-H), 
7.996-7.961 (m, 2H, Ar-H), 7.869-7.846 (m, 1H, Ar-H), 7.586-7.589 (m, 3H, Ar-H), 7.428-7.370 
(m, 3H, Ar-H), 4.747 (s, 1H, Methine), 1.566 (s, 2H, -NH2);  LCMS (MM:ES+APCI) 
(M+H)
+
394; Anal.Calcd for C24H15N3O3 : C 73.27, H 3.84, N 10.68;  Found: C 73.31; H, 3.88; 
N, 10.73. 
7g 2-amino-4-(4-(5,6-dichloropyridin-3-yl)phenyl)-5-oxo-4,5-dihydropyrano[3,2-
c]chromene-3-carbonitrile:  This compound was obtained by heating 2-amino-4-(4-
bromophenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 5) 
and (4,6-dichloropyridin-3-yl)boronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 
catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 4 ml of tetrahydrofuran 
solvent for 9.5 hours. 7g has been observed on TLC at Rf 0.51 under UV light and was isolated 
as white solid by column chromatography with 16% hexane:ethyl acetate system (84ml hexane: 
16ml ethyl acetate). 
IR νmax: 3320cm
-1 
ν(NH2), 2192cm
-1 
ν(CN), 1665cm
-1
ν(c-o),1046cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 8.625 (s, 1H, Ar-N-H), 8.462 (s, 1H, Ar-H), 7.772 (m, 1H, Ar-H), 7.595-7.501 (m, 1H, 
Ar-H), 7.386-7.324 (m, 2H, Ar-H), 7.003-6.896 (m, 3H, Ar-H), 3.725 (s, 1H, Methine); LCMS 
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(MM:ES+APCI) (M+H)
+
 463; Anal.Calcd for C24H13Cl2N3O3 : C 62.35, H 2.83, N 9.09;  Found: 
C 62.31, H 2.79, N 9.12. 
7h 2-amino-4-(6-methoxy-[1,1'-biphenyl]-3-yl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-
carbonitrile: This compound was obtained by heating 2-amino-4-(3-bromo-4-methoxyphenyl)-
5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile (1 mmol) (compound 5) and phenyl 
boronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—
Bi2O3 (0.5 mmol) base in 1 ml water and 4 ml of tetrahydrofuran solvent for 8 hours. 7h has been 
observed on TLC at Rf 0.56 under UV light and was isolated as yellow solid by column 
chromatography with 15% hexane:ethyl acetate system (85ml hexane: 15ml ethyl acetate). 
IR νmax:3286cm
-1 
ν(NH2), 2197cm
-1 
ν(CN), 1667cm
-1
ν(c-o),1052cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 7.797-7.776 (s, 1H, Ar-H), 7.772-7.7.52 (m, 1H, Ar-H), 7.491-7.467 (m, 2H, Ar-H), 
7.374-7.336 (m, 6H, Ar-H), 7.192-7.186 (m, 1H, Ar-H), 6.939-.917 (m, 1H, Ar-H), 3.867  (s, 
1H, Methine), 3.750-3.715 (s, 3H, -OCH3); LCMS (MM:ES+APCI) (M-H)
-
 421; Anal.Calcd for 
C26H18N2O4 : C 73.92, H 4.29, N 6.63;  Found: C 73.88, H4.26, N 6.67. 
7i 2-amino-4-(6-methoxy-2'-methyl-[1,1'-biphenyl]-3-yl)-5-oxo-4,5-dihydropyrano[3,2-
c]chromene-3-carbonitrile: This compound was obtained by heating 2-amino-4-(3-bromo-4-
methoxyphenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile (1 mmol) (compound 
5) and o-tolylboronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 
mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 4 ml of tetrahydrofuran solvent for 8.5 
hours. 7i has been observed on TLC at Rf 0.57 under UV light and was isolated as white solid by 
column chromatography with 15% hexane:ethyl acetate system (85ml hexane: 15ml ethyl 
acetate). 
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IR νmax: 3288cm
-1 
ν(NH2), 2196cm
-1 
ν(CN), 1668cm
-1
ν(c-o),1057cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 7.775-7.758 (m, 1H, Ar-H), 7.356-7.348 (m, 3H, Ar-H), 7.260 (m, 3H, Ar-H), 7.030-
6.902 (m, 4H, Ar-H), 4.629 (1H, Methine, s), 3.734 (3H, -OCH3, s), 2.069 (3H, -CH3, s); LCMS 
(MM:ES+APCI) (M-H)
-
 435; Anal.Calcd for C27H20N2O4 : C 74.30, H 4.62, N 6.42;  Found: 
C74.28, H 4.65, N 6.46. 
7j 2-amino-4-(3',6-dimethoxy-[1,1'-biphenyl]-3-yl)-5-oxo-4,5-dihydropyrano[3,2-
c]chromene-3-carbonitrile: This compound was obtained by heating 2-amino-4-(3-bromo-4-
methoxyphenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 
5) and (3-methoxyphenyl)boronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst 
(0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 4 ml of tetrahydrofuran solvent 
for 9.5 hours. 7j has been observed on TLC at Rf 0.50 under UV light and was isolated as brown 
solid by column chromatography with 16% hexane:ethyl acetate system (84ml hexane: 16ml 
ethyl acetate). 
IR νmax: 3287cm
-1 
ν(NH2), 2197cm
-1 
ν(CN), 1669cm
-1 
ν(c-o),1053cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 7.791-7.773 (s, 1H, Ar-H), 7.613-7.574 (m, 2H, Ar-H), 7.354-7.335 (m, 3H, Ar-H), 
7.260 (m, 1H, Ar-H), 7.065-7.037 (m, 2H, Ar-H), 6.936-6.847 (m, 2H, Ar-H), 6.847 (m, 11H, 
Ar-H), 3.811 (s, 1H, Methine), 3.779 (s, 6H -OCH3); 
13
C NMR (DMSO-D6, 75MHz) δ 161.52, 
160.25, 154.12, 152.74, 132.13, 126.98, 126.17, 125.01, 124.45, 123.85, 123.11, 122.92, 121.51, 
119.25, 116.52, 113.32, 110.59, 100.50, 60.15, 56.72, 55.91, 36.71; LCMS (MM:ES+APCI) (M-
H)
-
 451; Anal.Calcd for C27H20N2O5 : C 71.67, H 4.46, N 6.19;  Found: C 71.71, H 4.41, N 6.21. 
7k 2-amino-4-(6-methoxy-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-5-oxo-4,5-
dihydropyrano[3,2-c]chromene-3-carbonitrile: This compound was obtained by heating 2-
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amino-4-(3-bromo-4-methoxyphenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile 
(1 mmol) (compound 5) and (2-(trifluoromethyl)phenyl)boronic acid 6(1.2 mmol) at 70 
o
C in 
presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 
4 ml of tetrahydrofuran solvent for 8.2 hours. 7k has been observed on TLC at Rf 0.48 under UV 
light and was isolated as brown solid by column chromatography with 17% hexane:ethyl acetate 
system (83ml hexane: 17ml ethyl acetate). 
IR νmax: 3301cm
-1 
ν(NH2), 2198cm
-1 
ν(CN), 1671cm
-1 
ν(c-o),1053cm
-1 
ν(C=O);
1
H NMR (CDCl3, 300 
MHz):- δ 7.925-7.885 (m, 2H, Ar-H), 7.815 (s, 1H, Ar-H), 7.651-7.552 (m, 2H, Ar-H), 7.450-
7.321 (m, 3H, Ar-H), 7.250 (m, 2H, Ar-H), 6.982 (s, 1H, Ar-H), 4.297 (s, 1H, Methine), 3.306 
(s, 3H, -OCH3); 
13
C NMR (CDCl3, 75MHz) δ 162.19, 161.28, 159.14, 158.34, 133.65, 131.28, 
129.52, 125.87, 125.19, 124.57, 124.01, 123.85, 123.08, 122.12, 117.12, 115.28, 103.52, 59.28, 
55.71, 36.17;LCMS (MM:ES+APCI) (M+H)
+
 491; Anal.Calcd for C27H17F3N2O4 : C 66.12, H 
3.49, N 5.71;  Found: C 66.13, H 3.52, N 5.73. 
7l 2-amino-4-(4'-chloro-6-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-5-oxo-4,5-
dihydropyrano[3,2-c]chromene-3-carbonitrile: This compound was obtained by heating 2-
amino-4-(3-bromo-4-methoxyphenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile 
(1 mmol) (compound 5) and (4-chloro-3-(trifluoromethyl)phenyl)boronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml 
water and 4 ml of tetrahydrofuran solvent for 9 hours. 7l has been observed on TLC at Rf 0.47 
under UV light and was isolated as white solid by column chromatography with 17% 
hexane:ethyl acetate system (83ml hexane: 17ml ethyl acetate). 
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IR νmax: 3288cm
-1 
ν(NH2), 2198cm
-1 
ν(CN), 1671cm
-1 
ν(c-o),1055cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 7.819-7.799 (d, 1H, Ar-H), 7.638-7.616 (m, 2H, Ar-H), 7.599-7.571 (m, 2H, Ar-H), 
7.504 (m, 2H, Ar-H), 7.392-7.510 (m, 2H, Ar-H), 6.869-6.848 (s, 1H, Ar-H), δ 3.870 (s, 1H, 
Methine), δ 3.787 (s, 3H -OCH3); 
13
C NMR (DMSO-D6, 75MHz) δ 161.57, 160.16, 158.91, 
144.15, 135.46, 133.48, 132.19, 125.45, 124.89, 124.25, 123.10, 122.59, 121.85, 121.41, 119.32, 
116.28, 114.11, 113.42, 101.41, 59.12, 55.72, 36.29; LCMS (MM:ES+APCI) (M-H)
-
 523; 
Anal.Calcd for C27H16ClF3N2O4 : C 61.78,  H 3.07,  N 5.34;  Found: C 61.74, H 3.05, N 5.30. 
7m 2-amino-4-(4-methoxy-3-(pyridin-3-yl)phenyl)-5-oxo-4,5-dihydropyrano[3,2-
c]chromene-3-carbonitrile: This compound was obtained by heating 2-amino-4-(3-bromo-4-
methoxyphenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile(1 mmol) (compound 
5) and pyridin-3-ylboronic acid 6(1.2 mmol) at 70 
o
C in presence of Pd(dppf)2Cl2 catalyst (0.001 
mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 4 ml of tetrahydrofuran solvent for 8 
hours. 7m has been observed on TLC at Rf 0.51 under UV light and was isolated as white solid 
by column chromatography with 16% hexane:ethyl acetate system (84ml hexane: 16ml ethyl 
acetate). 
IR νmax: 3292cm
-1 
ν(NH2), 2199cm
-1 
ν(CN), 1674cm
-1 1 
ν(c-o),1066cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 8.718-8.672 (s, 1H, Ar-H), 8.608-8.511 (s, 1H, Ar-H), 8.112-7.941 (m, 2H, Ar-H), 
7.819-7.766 (m, 1H, Ar-H), 7.606-7.588 (m, 2H, Ar-H), 7.518-7.310 (m, 4H, Ar-H), 4.627 (s, 
1H, Methine), 3.656 (s, 3H -OCH3) LCMS (MM:ES+APCI) (M-H)
-
 422; Anal.Calcd for 
C25H17N3O4 : C 70.91, H 4.05, N 9.92;  Found: C 70.89, H 4.09, N 9.90. 
7n 2-amino-4-(3-(4,6-dichloropyridin-3-yl)-4-methoxyphenyl)-5-oxo-4,5-
dihydropyrano[3,2-c]chromene-3-carbonitrile: This compound was obtained by heating 2-
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amino-4-(3-bromo-4-methoxyphenyl)-5-oxo-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile 
(1 mmol) (compound 5) and (4,6-dichloropyridin-3-yl)boronic acid 6(1.2 mmol) at 70 
o
C in 
presence of Pd(dppf)2Cl2 catalyst (0.001 mmol), SCS—Bi2O3 (0.5 mmol) base in 1 ml water and 
4 ml of tetrahydrofuran solvent for 8.5 hours. 7n has been observed on TLC at Rf 0.48 under UV 
light and was isolated as brown solid by column chromatography with 16% hexane:ethyl acetate 
system (84ml hexane: 16ml ethyl acetate). 
IR νmax: 3228cm
-1 
ν(NH2), 2193 cm
-1 
ν(CN), 1671cm
-1
ν(c-o),1051cm
-1 
ν(C=O); 
1
H NMR (CDCl3, 300 
MHz):- δ 8.601 (s, 1H, Ar-N-CH), 7.716-7.182 (m, 8H, Ar-H), 4.112 (s, 1H, Methine), 3.603 (s, 
3H, -OCH3); LCMS (MM:ES+APCI) (M+H)
+
 493; Anal.Calcd for C25H15Cl2N3O4 : C 60.99, H 
3.07, N 8.54;  Found: C 60.96, H 3.05, N 8.59. 
Substrate preparation: Briefly, a working solution of 1mM DMPC (Substrate) was prepared in 
methanol containing 2mM Triton X-100 in Milli-Q water. The resulting substrate solution was 
spun at 1,500xg for 5min to form uniform mixed micelles.  
LPC standardcurve: LPC (1-myristoyl-2-hydroxy-Sn-glycerol-3-phosphocholine) standard 
curve was constructed using different LPC concentrations ranging from 0 to 100µM as reported 
earlier
[31]
. Briefly, total reaction mixture of 100µL containing activity buffer (50mM Tris, pH 
7.5, 10mM CaCl2) and 2mM LPC containing 4mM Triton X-100 (1:2 ratio) and incubated for 5 
min at 37ºC.  Quenching solution was added and vortexed for 30 Sec and incubated for 5 min at 
RT. 2µL of reaction mixture was pipetted to measure RFU as described earlier.  
Neutralization of VRV-PL-VIIIa (sPLA2) by the title compounds: sPLA2 activity was 
assayed according to the method
[32]
. Briefly, a 50µl activity buffer containing 50mM Tris-HCl 
buffer pH 7.5, 10mM CaCl2 and 10µl substrate stock were added and incubated for 5 min at 
37ºC. Activity was initiated by adding 10ng of sPLA2 alone or pre incubated with different 
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concentration of DCMB analogues ranging from 0-120µM for 5min at 37°C. Reaction mixture 
was incubated for 45 min at 37ºC. 50µl of quenching solution was added at final concentration of 
2mM NaN3, 50µM ANS and 50mM EGTA, vortexed for 30 sec and incubated for 5 min at RT. 
2µl of this solution was pipetted to measure Relative fluorescence unit (RFU) in a Nano drop 
ND3300 Ver 2.8 using excitation with UV-LED (370 ±10nm) and emission was recorded at 
480nm in dark condition. Enzyme activity was calculated by Eq (1), where ∆RFU is the change 
in RFU of test (with sPLA2) with respect to control (without sPLA2) in presence of inhibitor. 
The resultant RFU is compared with standard curve of LPC to determine the sPLA2 activity in 
presence of inhibitor. 4
th
 parameter logical (4PL) fit module of Graphpad Prism 6.05 was used to 
compute IC50 values.  
Equation 1 
∆RFULPC = RFUc – RFUt  
Molecular Docking Studies: We docked the series of fourteen synthesized compounds to the 
crystal structure of PLA2 from Russel's viper in complex with nimesulide (PDB: 1ZWP). We 
used identical settings as in an earlier study on imidazopyridine-based PLA2inhibitors docking in 
MOE. The protocol included a pharmacophore filter during docking to enforce a hydrogen bond 
acceptor feature in the position of the nitro group of nimesulide. Predicted binding modes were 
visualized in Pymol
[33-35]
. 
CONCLUSION 
In conclusion, we herein report a simple, efficient, catalyst free and one potsynthetic route 
to prepare tri-substituted-condensed-imidazopyridines and ourin silico target prediction 
presented PLA2 as a likely target for the newly synthesized compounds. The prediction 
was experimentally validated using indirect haemolytic assay. Of the new compounds 
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synthesized, 1-(2-Methyl-8-naphthalen-1-yl-imidazo [1,2-α]pyridine-3-yl)-ethanone was 
identified as the lead compound with an IC50 value of 14.3 µM. Molecular docking 
analysis displayed that the imidazopyridine compounds could make a favourable π-π 
stacking interactions with Trp-31. Exploration of PLA2 inhibitory activity of 
imidazopyridine derivatives contributes to the development of the title compounds as 
therapeutic agents to block the PLA2 associated inflammatory diseases. Thus, synthesis 
of more imidazopyridine derivatives and optimization of their biological activity 
according to the identified structure-activity relationship is envisaged. 
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Figure 1: Structural representation of in silico ranked structure ZINC0062553 (DCMB) and its 
analogues. 
Figure 2: Synthesis scheme for DCMB analogues 7(a-n).  
Figure 3: Molecular interaction studies of novel ligands that targets PLA2. Predicted molecular 
interactions between PLA2 and DCMB analogues: PLA2 is shown as grey cartoon with semi-
transparent surface representation. Main interaction centres Asp-49, Gly-32, Trp-31, and Gly-30 
(from left to right) are highlighted as lines in atomic colouring. A) Binding mode of nimesulide 
within the co-crystal structure used for docking (PDB: 1ZWP, 
[4]
).  a and 7b are predicted to bind 
in two different modes to PLA2. Both of them replace the nitro group of nimesulide by a cyano 
group and show π-π interactions with Trp-31 but form different molecular interactions via the 
amine group (7a: Asp-49, 7b: Gly-30). 
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Figure 3 
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Table 1: List of ranked compounds targeting PLA2 based on the designing of MOLPRINT 
2D. 
Rank Zinc Accession Compound name Structure Probability of 
Activity 
1 ZINC00299345 
2-
(phenoxycarbonyl)p
henyl 2-furoate 
 
2531.0 
2 ZINC08427108 
(5R,5'R)-5,5'-
oxybis(3,4-
dibromofuran-
2(5H)-one) 
 
2295.8 
3 ZINC08427105 
(5S,5'S)-5,5'-
oxybis(3,4- 
 
dibromofuran-
2(5H)-one) 
 
2295.8 
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4 ZINC00625534 
4-(2-amino-3-cyano-
5-oxo-4H,5H-
pyrano[3,2-
c]chromen-4-yl)-2-
methoxyphenyl 
benzoate 
 
1819.7 
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Table2: Newly synthesized DCMB analogues 
Entry 1 6 7(a-n)
 a
Yield% 
1 OH
Br  
B
HO OH
 
O
O
NH2
O
N
 
7a 
92 
2 OH
Br  
B
HO OH
 
O
O
NH2
O
N
 
7b 
90 
3 OH
Br  
B
HO OH
O  O
O
NH2
O
N
O
 
7c 
89 
4 OH
Br  
B
HO OH
CF3
 
O
O
NH2
O
N
CF3
 
7d 
84 
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 5 OH
Br  
B
HO OH
Cl
CF3
 
O
O
NH2
O
N
CF3
Cl  
7e 
85 
6 OH
Br  
N
B
HO OH
 O
O
NH2
O N
N
 
7f 
89 
7 OH
Br  
N
B
HO OH
Cl
Cl
 
O
O
NH2
O N
N
Cl
Cl
 
7g 
93 
8 
HO
O
Br
 
B
HO OH
 
O
O
NH2
O O
N
 
7h 
91 
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9 HO
O
Br
 
B
HO OH
 
O
O
NH2
O O
N
 
7i 
92 
10 HO
O
Br
 
B
HO OH
O  
O
O
NH2
O O
N
O
 
7j 
90 
11 HO
O
Br
 
B
HO OH
CF3
 
O
O
NH2
O O
N
F3C
 
7k 
84 
12 
HO
O
Br
 
B
HO OH
Cl
CF3
 
O
O
NH2
O O
N
Cl
CF3
 
7l 
87 
13 HO
O
Br
 
N
B
HO OH
 O
O
NH2
O O
N
N
 
7m 
86 
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14 HO
O
Br
 
N
B
HO OH
Cl
Cl
 
O
O
NH2
O O
N
N
ClCl
 
7n 
83
 
a 
Isolated  
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Table 3: In-vitro inhibition of PLA2 by DCMB analogues. 
Sl. 
No 
Ligands IC50 (µM) 
1 7a 13.61µM 
2 7b 12.50µM 
3 7c 22.67µM 
4 7d ND
a
 
5 7e ND 
6 7f 40.35µM 
7 7g 63.85µM 
8 7h Inactive 
9 7i 57.03µM 
10 7j 18.95µM 
11 7k ND 
12 7l ND 
13 7m 20.54µM 
14 7n 18.94µM 
a
ND, not determined. 
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